Alaska Permanent Fund Corp Sells 78,539 Shares of SPDR S&P Biotech ETF (NYSEARCA:XBI)

Alaska Permanent Fund Corp cut its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 75.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,418 shares of the exchange traded fund’s stock after selling 78,539 shares during the quarter. Alaska Permanent Fund Corp’s holdings in SPDR S&P Biotech ETF were worth $2,289,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Sharper & Granite LLC grew its position in shares of SPDR S&P Biotech ETF by 3.3% during the 4th quarter. Sharper & Granite LLC now owns 12,053 shares of the exchange traded fund’s stock valued at $1,085,000 after acquiring an additional 380 shares during the period. Breakwater Capital Group raised its stake in shares of SPDR S&P Biotech ETF by 16.5% in the fourth quarter. Breakwater Capital Group now owns 5,266 shares of the exchange traded fund’s stock worth $474,000 after buying an additional 744 shares during the period. 180 Wealth Advisors LLC lifted its position in shares of SPDR S&P Biotech ETF by 9.7% during the 4th quarter. 180 Wealth Advisors LLC now owns 4,238 shares of the exchange traded fund’s stock valued at $382,000 after buying an additional 373 shares in the last quarter. Fortis Advisors LLC grew its stake in shares of SPDR S&P Biotech ETF by 12.3% during the 4th quarter. Fortis Advisors LLC now owns 5,950 shares of the exchange traded fund’s stock valued at $536,000 after acquiring an additional 650 shares during the period. Finally, Global Financial Private Client LLC increased its holdings in SPDR S&P Biotech ETF by 8.5% in the 4th quarter. Global Financial Private Client LLC now owns 9,326 shares of the exchange traded fund’s stock worth $840,000 after acquiring an additional 727 shares in the last quarter.

SPDR S&P Biotech ETF Price Performance

Shares of NYSEARCA:XBI opened at $88.55 on Thursday. The firm’s 50 day simple moving average is $94.72 and its two-hundred day simple moving average is $97.00. The company has a market capitalization of $6.75 billion, a P/E ratio of 11.47 and a beta of 1.11. SPDR S&P Biotech ETF has a 1-year low of $81.14 and a 1-year high of $105.47.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.